Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Debt: 2022-2025

Historic Non-Current Debt for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $207.1 million.

  • Phathom Pharmaceuticals' Non-Current Debt rose 17.85% to $207.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $207.1 million, marking a year-over-year increase of 17.85%. This contributed to the annual value of $201.4 million for FY2024, which is 46.12% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Non-Current Debt stood at $207.1 million for Q3 2025, which was up 0.95% from $205.1 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Non-Current Debt's 5-year high stood at $207.1 million during Q3 2025, with a 5-year trough of $91.0 million in Q1 2022.
  • Moreover, its 3-year median value for Non-Current Debt was $174.4 million (2024), whereas its average is $158.9 million.
  • Data for Phathom Pharmaceuticals' Non-Current Debt shows a peak YoY spiked of 78.34% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' Non-Current Debt (Quarterly) stood at $95.3 million in 2022, then spiked by 44.69% to $137.8 million in 2023, then spiked by 46.12% to $201.4 million in 2024, then grew by 17.85% to $207.1 million in 2025.
  • Its last three reported values are $207.1 million in Q3 2025, $205.1 million for Q2 2025, and $203.2 million during Q1 2025.